Phase 3 results posted, week of October 12, 2026: 11 industry trials
Industry sponsors posted results for 11 Phase 3 trials on ClinicalTrials.gov so far in the week of October 12 to 18, 2026. Together the trials enrolled 4,030 participants; the largest, Sanofi's AERIFY-1 trial, enrolled 1,127.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, October 18, 2026.
The trials
- Sanofi posts results of Phase 3 itepekimab trial in COPD. Sponsor: Sanofi. Condition: Chronic Obstructive Pulmonary Disease. Intervention: Itepekimab SAR440340. Phase: Phase 3. Enrollment: 1,127 (actual). Results first posted October 15, 2026. Record: NCT04701983 (AERIFY-1).
- Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study. Sponsor: Eli Lilly and Company. Condition: Type 2 Diabetes. Interventions: Orforglipron, Dapagliflozin. Phase: Phase 3. Enrollment: 962 (actual). Results first posted October 16, 2026. Record: NCT06192108 (ACHIEVE-2).
- Lee's Pharmaceutical posts results of Phase 3 ciprofloxacin-fluocinolone otic solution trial. Sponsor: Lee's Pharmaceutical Limited. Condition: Acute Otitis Externa. Interventions: Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution, Ciprofloxacin 0.3% solution. Phase: Phase 3. Enrollment: 600 (actual). Results first posted October 13, 2026. Record: NCT04636957.
- United Therapeutics posts results of Phase 3 TETON-2 inhaled treprostinil study. Sponsor: United Therapeutics. Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease. Interventions: Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer. Phase: Phase 3. Enrollment: 597 (actual). Results first posted October 15, 2026. Record: NCT05255991 (TETON-2).
- Eli Lilly posts results of Phase 3 lebrikizumab trial in atopic dermatitis. Sponsor: Eli Lilly and Company. Condition: Atopic Dermatitis. Interventions: Lebrikizumab, Topical Corticosteroid. Phase: Phase 3. Enrollment: 301 (actual). Results first posted October 16, 2026. Record: NCT06280716.
- ACADIA posts results of Phase 3 carbetocin nasal spray trial in Prader-Willi syndrome. Sponsor: ACADIA Pharmaceuticals Inc. Condition: Hyperphagia in Prader-Willi Syndrome. Intervention: Carbetocin. Phase: Phase 3. Enrollment: 175 (actual). Results first posted October 15, 2026. Record: NCT06173531.
- Hoffmann-La Roche posts results of Phase 3 obinutuzumab trial in childhood nephrotic syndrome. Sponsor: Hoffmann-La Roche. Condition: Childhood Idiopathic Nephrotic Syndrome. Interventions: Obinutuzumab, MMF, Prednisone, Methylprednisolone, Acetaminophen/ Paracetamol, Diphenhydramine Hydrochloride. Phase: Phase 3. Enrollment: 85 (actual). Results first posted October 14, 2026. Record: NCT05627557 (INShore).
- Vertex posts results of Phase 3 ELX/TEZ/IVA study in infants. Sponsor: Vertex Pharmaceuticals Incorporated. Condition: Cystic Fibrosis. Interventions: ELX/TEZ/IVA, IVA. Phase: Phase 3. Enrollment: 67 (actual). Results first posted October 15, 2026. Record: NCT05882357.
- Ultragenyx posts results of Phase 3 DTX401 trial in Glycogen Storage Disease Type Ia. Sponsor: Ultragenyx Pharmaceutical Inc. Condition: Glycogen Storage Disease Type IA. Interventions: DTX401, Oral prednisolone. Phase: Phase 3. Enrollment: 52 (actual). Results first posted October 14, 2026. Record: NCT05139316.
- Good Molecules posts results of Phase 3 facial toner study. Sponsor: Good Molecules, LLC. Condition: Hyperpigmentation. Intervention: Facial Toner. Phase: Phase 3. Enrollment: 49 (actual). Results first posted October 13, 2026. Record: NCT07136766.
- Nektar posts results of Phase 2/3 NKTR-255 trial in relapsed/refractory large B-cell lymphoma. Sponsor: Nektar Therapeutics. Conditions: Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma. Interventions: NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg. Phase: Phase 2/Phase 3. Enrollment: 15 (actual). Results first posted October 16, 2026. Record: NCT05664217.
By the numbers
- Trials: 11, from 10 lead sponsors.
- Participants: 4,030 in all across 11 trials; median 175 per trial.
- Largest: Sanofi's AERIFY-1 trial, 1,127. Smallest: Nektar Therapeutics' NKTR-255 at 1.5 µg/kg trial, 15.
- Sponsors with more than one trial: Eli Lilly and Company (2).
- Phases as registered: 10 Phase 3, 1 Phase 2/Phase 3.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Registry results are summary data the sponsor posted; the record link opens them in full.